GREAT POINT PARTNERS LLC

Fundamental concentrated ★Signal healthcare specialist (100%) CIK 1281446
League rank
#374
in Fundamental concentrated · #905 overall
Long book
$408.3M
Q1 2026
Positions
39
Top-10 weight
54%
concentration
Last quarter
+17.6%
SPY +14.8%
Turnover
55%
of book per quarter

Strategy in plain words

auto-generated from filings

GREAT POINT PARTNERS LLC is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $408.3M US long book across 39 positions.

The portfolio is concentrated: the top 10 names carry 54% of the portfolio. Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: APOGEE THERAPEUTICS INC, VOR BIOPHARMA INC, ZURA BIO LTD, AMYLYX PHARMACEUTICALS INC, NEKTAR THERAPEUTICS.

Over the last 9 quarters its long book ran on average 7.3pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.

Implied long-book return vs S&P 500

methodology: positions priced quarterly, no shorts/options
Fund long book S&P 500
Q1 2024
-11.4%
Q2 2024
-0.7%
Q3 2024
-26.1%
Q4 2024
-31.8%
Q1 2025
+12.5%
Q2 2025
+117.4%
Q3 2025
+13.9%
Q4 2025
+14.9%
Q1 2026
+17.6%

Sector allocation

Healthcare
97%
Other
3%

Long book by quarter

$641.6M
Q1 2024
$522.0M
Q2 2024
$331.4M
Q3 2024
$212.2M
Q4 2024
$184.0M
Q1 2025
$153.8M
Q2 2025
$239.5M
Q3 2025
$308.4M
Q4 2025
$408.3M
Q1 2026

What does GREAT POINT own?

Q1 2026 13F
CompanySectorSharesValue% of bookChange
APGE APOGEE THERAPEUTICS INCHealthcare374.0K$31.5M7.7%Held
VOR VOR BIOPHARMA INCHealthcare1.8M$31.2M7.6%+27.7%
ZURA ZURA BIO LTDHealthcare4.2M$25.1M6.1%+10.5%
AMLX AMYLYX PHARMACEUTICALS INCHealthcare1.8M$24.3M6.0%Held
NKTR NEKTAR THERAPEUTICSHealthcare316.5K$22.8M5.6%+50.2%
SLGL SOL-GEL TECHNOLOGIES LTDHealthcare274.4K$21.7M5.3%New
ALMS ALUMIS INCHealthcare856.1K$18.9M4.6%New
DRUG BRIGHT MINDS BIOSCIENCES INCHealthcare220.0K$16.1M3.9%New
ANNX ANNEXON INCHealthcare2.5M$13.8M3.4%New
4XC1 KALVISTA PHARMACEUTICALS INC—675.0K$13.6M3.3%-1.6%
IMVT IMMUNOVANT INCHealthcare545.6K$13.6M3.3%-27.3%
JBIO JADE BIOSCIENCES INCHealthcare964.5K$13.6M3.3%+19.6%
CTNM CONTINEUM THERAPEUTICS INC-AHealthcare800.2K$10.5M2.6%0.0%
ZBIO ZENAS BIOPHARMA INCHealthcare524.1K$10.2M2.5%New
NGNE NEUROGENE INCHealthcare500.0K$10.1M2.5%+42.9%
MLTX MOONLAKE IMMUNOTHERAPEUTICSHealthcare500.0K$9.3M2.3%New
CLYM CLIMB BIO INCHealthcare1.3M$9.1M2.2%+36.2%
ORKA ORUKA THERAPEUTICS INCHealthcare183.3K$9.0M2.2%Held
EPRX EUPRAXIA PHARMACEUTICALS INCHealthcare1.2M$8.7M2.1%Held
VERA VERA THERAPEUTICS INCHealthcare199.3K$8.0M2.0%New
EVMN EVOMMUNE INCHealthcare325.0K$7.5M1.8%Held
LBRX LB PHARMACEUTICALS INCHealthcare300.0K$7.4M1.8%New
CMPX COMPASS THERAPEUTICS INCHealthcare1.4M$7.1M1.7%New
SCYX SCYNEXIS INCHealthcare7.6M$6.9M1.7%New
PALI PALISADE BIO INCHealthcare3.4M$6.0M1.5%New
CNTX CONTEXT THERAPEUTICS INCHealthcare2.2M$5.9M1.4%-52.2%
RLMD RELMADA THERAPEUTICS INCHealthcare842.1K$5.9M1.4%New
UNCY UNICYCIVE THERAPEUTICS INCHealthcare796.6K$5.2M1.3%Held
TENX TENAX THERAPEUTICS INCHealthcare327.3K$5.2M1.3%New
PMN PROMIS NEUROSCIENCES INCHealthcare371.4K$4.7M1.2%New
CGEM CULLINAN THERAPEUTICS INCHealthcare300.0K$4.3M1.0%-52.7%
IMMX IMMIX BIOPHARMA INCHealthcare350.0K$3.2M0.8%New
RZLT REZOLUTE INCHealthcare951.8K$2.9M0.7%Held
PHVS PHARVARIS NVHealthcare82.8K$2.3M0.6%Held
HUMA HUMACYTE INCHealthcare3.8M$2.3M0.6%New
AVTX AVALO THERAPEUTICS INCHealthcare124.7K$1.9M0.5%Held
ALKS ALKERMES PLCHealthcare50.0K$1.8M0.4%New
IRD OPUS GENETICS INCHealthcare324.3K$1.5M0.4%New

13F filing history

PeriodFormFiledEntriesReported valueFlagsSource
Q1 202613F-HRMay 15, 202642$435.1M canonicalSEC ↗
Q4 202513F-HRFeb 17, 202629$308.4M canonicalSEC ↗
Q3 202513F-HRNov 14, 202530$242.5M canonicalSEC ↗
Q2 202513F-HRAug 14, 202526$153.8M canonicalSEC ↗
Q1 202513F-HRMay 15, 202532$188.8M canonicalSEC ↗
Q4 202413F-HRFeb 14, 202526$212.2M canonicalSEC ↗
Q3 202413F-HRNov 13, 202430$339.8M canonicalSEC ↗
Q2 202413F-HRAug 14, 202433$522.0M canonicalSEC ↗
Q1 202413F-HRMay 15, 202435$641.6M canonicalSEC ↗

Similar funds

LILLY ENDOWMENT INCBAKER BROS. ADVISORS LPINVESTOR ABCarlyle Group Inc.GREENLEAF TRUSTAvoro Capital Advisors LLCRTW INVESTMENTS, LPRA CAPITAL MANAGEMENT, L.P.DEERFIELD MANAGEMENT COMPANY, L.P.Simplify Asset Management Inc.PERCEPTIVE ADVISORS LLCParadigm Biocapital Advisors LP